Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "disease"

2839 News Found

Innovent inks agreement with Roche for Novel DLL3 ADC
News | January 02, 2025

Innovent inks agreement with Roche for Novel DLL3 ADC

Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009


Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
News | January 01, 2025

Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist

Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535


Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals
News | December 31, 2024

Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals

Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million


Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio
News | December 31, 2024

Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio

The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre


Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
Drug Approval | December 27, 2024

Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH


Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
News | December 24, 2024

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007


USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Drug Approval | December 21, 2024

USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC

Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the


Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
News | December 20, 2024

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery